Original Research Article

Quantitative estimation of sitagliptin and dapagliflozin propanediol monohydrate in synthetic mixture using 1st order derivative spectroscopy simultaneous spectrophotometric analysis

Shivani Jani¹*, Rashmi Shukla¹, Pinak Patel¹, Binny Mehta¹, Krunal Detholia²

¹ Dept. of Pharmaceutical Quality Assurance, Smt. S. M. Shah Pharmacy College, Ahmedabad, Gujarat, India
² Dept. of Pharmaceutics, Smt. S. M. Shah Pharmacy College, Gujarat, India

A R T I C L E I N F O

Article history:
Received 02-03-2022
Accepted 15-03-2022
Available online 09-04-2022

Keywords:
Sitagliptin
Dapagliflozin
Derivative spectroscopy
Zero crossover point
Analytical method validation

A B S T R A C T

Current research paper describes highly specific and reproducible 1st order derivative spectroscopic method for quantitative analysis of Sitagliptin which is a DPP4 inhibitors and Dapagliflozin which is SGLT2 inhibitors from its synthetic mixture. Both drugs are from Anti Diabetics class. Present analytical method was developed on Shimadzu double beam spectrophotometer equipped with UV probe 2,42 as software using methyl alcohol as solvent. Quantification of Sitagliptin was carried out at zero cross over point of Dapagliflozin that is 275 nm and for Dapagliflozin, it was achieved at 232 nm which is zero cross over point of Sitagliptin. Method shows linear response in the range of 25-125 g/mL of Sitagliptin and 2.5-12.5 g/mL of Dapagliflozin. Method was found to be accurate with recovery between 99.3 – 100.1 % for Sitagliptin and 98.2 – 100.7 % for Dapagliflozin. The developed method was validated as per ICH Q2 R1 guidelines and was successfully applied for quantitative analysis of synthetic mixture of Sitagliptin and Dapagliflozin.

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

Sitagliptin (SITA) acting as Anti Diabetic agent (Dipeptidyl peptidase-4 inhibitor) which boosts post prandial insulin release, decrease Glucagon secretion and lower mean time as well as fasting blood glucose in type 2 diabetes.¹ This agent is used in combination with other oral hypoglycemic agents. Dapagliflozin (DAPA) acting as Sodium-Glucose cotransporter-2(SGLT2) inhibitors. This agent is used in combination with diet and exercise to improve glycemic control in adult with type -2 Diabetes. SGLT 2 is major transporter of glucose whose inhibition induces glucosuria and lower blood sugar in type 2 diabetes mellitus.² According to the clinical trial study of real-
addition, derivative spectroscopy aids virtue of specificity to the analytical method due to estimation at Zero Cross Over point (ZCP). So for the same reason derivative spectroscopy was selected as method of choice from all other multi component UV spectrometric methods.

Fig. 1: Zero cross over point of SITA

Fig. 2: Zero cross over point of DAPA

Fig. 3: Overlain D1 spectra of SITA and DAPA

Fig. 4: Determination of DAPA at ZCP of SITA (at 232 nm)

Fig. 5: Determination of SITA at ZCP of DAPA (at 275 nm)

Fig. 6: D1 Spectra of standard mixture of SITA (25-125 μg/mL) and DAPA (2.5-12.5 μg/mL) for linearity study

Fig. 7: Regression analysis of SITA (25-125 μg/ml) at 275 nm
Table 1: Preparation of solutions for accuracy studies

| Preparation of solutions for Accuracy studies | 50% | 100% | 150% |
|----------------------------------------------|-----|------|------|
| Placebo                                      | 2.5 mg of DAPA and 25 mg of SITA in 10 ml calibrated volumetric flask | 5 mg of DAPA and 50 mg of SITA in 10 ml calibrated volumetric flask | 7.5 mg of DAPA and 75 mg of SITA in 10 ml calibrated volumetric flask |

Contents diluted up to 10 ml calibrated volumetric flask with Methyl Alcohol and filter the solution (A) Take 1 ml of this filtrate and dilute up to 10 ml with Methyl alcohol (B) To achieve final concentration, 1 ml of solution B diluted up to 10 ml with Methyl Alcohol (2.5+25 µg/ml) To achieve final concentration, 1 ml of solution B diluted up to 10 ml with Methyl Alcohol (5+50 µg/ml) To achieve final concentration, 1 ml of solution B diluted up to 10 ml with Methyl Alcohol (7.5+75 µg/ml)

Table 2: Linearity data of SITA

| Sr. No. | Concentration (µg/mL) | Mean (D₁ abs.) + S.D. | R.S.D. (%) |
|---------|-----------------------|-----------------------|------------|
| 1       | 25                    | -0.0062 ± 0.00007     | 1.2031     |
| 2       | 50                    | -0.0131 ± 0.00012     | 0.9118     |
| 3       | 75                    | -0.0208 ± 0.00012     | 0.6081     |
| 4       | 100                   | -0.0284 ± 0.00014     | 0.5160     |
| 5       | 125                   | -0.0367 ± 0.00008     | 0.2177     |

Table 3: Linearity data of DAPA

| Sr. No. | Concentration (µg/mL) | Mean (D₁ abs.) + S.D. | R.S.D. (%) |
|---------|-----------------------|-----------------------|------------|
| 1       | 2.5                   | -0.0057 ± 0.00004     | 0.8534     |
| 2       | 5.0                   | -0.0128 ± 0.00011     | 0.8879     |
| 3       | 7.5                   | -0.0192 ± 0.00012     | 0.6378     |
| 4       | 10                    | -0.0268 ± 0.00016     | 0.618      |
| 5       | 12.5                  | -0.0326 ± 0.00011     | 0.3568     |

Table 4: Repeatability data of SITA at 275 nm (n= 5 determinations)

| Sr no. | 25   | 50   | 75   | 100  | 125  |
|--------|------|------|------|------|------|
| Mean   | -0.0062 | -0.0133 | -0.0208 | -0.0285 | -0.0368 | -0.0368 | -0.0368 | -0.0368 | -0.0368 |
| S.D.   | 0.00007 | 0.00012 | 0.00012 | 0.00014 | 0.00008 |
| R.S.D. (%) | 1.2031 | 0.9118 | 0.6081 | 0.5160 | 0.2177 |

Table 5: Repeatability data of DAPA at 323 nm (n= 5 determinations)

| Sr no. | 2.5   | 5     | 7.5   | 10    | 12.5  |
|--------|-------|-------|-------|-------|-------|
| Mean   | -0.0057 | -0.0130 | -0.0193 | -0.0265 | -0.0328 | -0.0328 | -0.0327 | -0.0326 | -0.0328 |
| S.D.   | 0.00004 | 0.00011 | 0.00012 | 0.00016 | 0.00011 |
| R.S.D. (%) | 0.8534 | 0.8879 | 0.6378 | 0.6158 | 0.3568 |
Table 6: Intraday and inter day precision data of SITA (n = 3 determinations)

| Concentration (µg/ml) | Intraday Mean + SD    | %RSD    | Inter-Day Mean + SD    | %RSD    |
|-----------------------|-----------------------|---------|------------------------|---------|
| 25                    | -0.0062 ± 0.00007     | 1.2031  | -0.0062 ± 0.00006      | 1.0200  |
| 75                    | -0.0208 ± 0.00012     | 0.6081  | -0.0208 ± 0.00013      | 0.6509  |
| 125                   | -0.0367 ± 0.00008     | 0.2177  | -0.0367 ± 0.00008      | 0.2437  |

Table 7: Intraday and inter day precision data for DAPA (n = 3 determinations)

| Concentration (µg/ml) | Intraday Mean + SD    | %RSD    | Inter-Day Mean + SD    | %RSD    |
|-----------------------|-----------------------|---------|------------------------|---------|
| 2.5                   | -0.0057 ± 0.00004     | 0.8534  | -0.0055 ± 0.00004      | 0.8842  |
| 7.5                   | -0.0192 ± 0.00012     | 0.6378  | -0.0192 ± 0.00010      | 0.5300  |
| 12.5                  | -0.0326 ± 0.00011     | 0.3568  | -0.0327 ± 0.00010      | 0.3349  |

Table 8: Accuracy data of SITA and DAPA by derivative spectroscopy method

| Level of spiking | Total placebo (mg) | Amount of std. drug added (µg/ml) | Amount of drug recovered (µg/ml) | % Recovery |
|-----------------|--------------------|----------------------------------|---------------------------------|------------|
| Unspiked        | -                  | SITA 25                          | 24.88 ± 0.011                   | 100.1 ± 0.47 |
| 50 %            | 25                 | DAPA 2.5                         | 2.48 ± 0.004                    | 99.0 ± 0.18 |
| 100 %           | 50                 | SITA 49.67 ± 0.008               | 5.03 ± 0.212                    | 100.7 ± 0.42 |
| 150 %           | 75                 | DAPA 75.66 ± 0.607               | 7.36 ± 0.004                    | 98.2 ± 0.78 |

Table 9: Assay of synthetic mixture by validated 1st order derivative spectroscopic method

| Drug      | Amount taken (µg/mL) | Amount recovered (µg/mL) | % Assay |
|-----------|----------------------|--------------------------|---------|
| SITA      | 125                  | 124.99 ± 0.6             | 100.0 ± 0.6 |
| DAPA      | 12.5                 | 12.6 ± 0.7               | 100.6 ± 0.7 |

Fig. 8: Regression Analysis of DAPA (2.5-12.5 µg/ml) at 232 nm

2. Materials and Methods

2.1. Materials

DAPA (99.98% pure) and SITA (99.96% pure) were obtained as gift sample for research purpose from, Cadila Healthcare Ltd., Sanand. Methyl alcohol (LR grade) was purchase from S.D. fines.

2.2. Instrument and experimental conditions

Spectrophotometric analysis was performed on shimadzu UV-1800 double beam spectrophotometer having path length of 1 cm matched pair of quartz cells. Obtained spectra of SITA and DAPA were derivatized 1st order using UV probe 2.42 as software at delta l of 10 nm

2.3. Preparation of master stock solution

For the method development purpose, 10 mg of SITA was weighed and diluted to 10 mL (1000 µg/mL) and was further diluted to give final concentration of 250 µg/mL. In similar way 50 mg of DAPA was weighed and diluted to 100 ml (500 µg/mL) and was further diluted to give final concentration of 25 µg/mL.

2.4. Selection of analytical wavelength

The working standards of SITA (25-125 µg/ml) and DAPA (2.5-12,5 µg/ml) were prepared in 10 ml volumetric flask using methyl alcohol as a solvent. They were scanned in the UV range of 200 – 400 nm and D0 spectra is recorded by UV spectrophotometer. All the D0 spectra of SITA and DAPA were transformed into D1 spectra with the help of UV probe 2.42 software. For confirmation of D1 spectra of SITA and
DAPA, D\textsuperscript{0} and D\textsuperscript{1} spectra of the same were overlapped.

2.5. Preparation of solutions for analytical method validation

2.5.1. Preparation of solution for linearity and range
To check linearity of method, SITA was prepared in the concentration range of 25-125 \(\mu\)g/ml and DAPA was prepared in the range of 2.5-12.5 \(\mu\)g/ml from master stock solution in 10 ml volumetric flask. When D\textsuperscript{1} absorbance was plotted against concentration, non-linearity was observed above 150 \(\mu\)g/ml for SITA and above 20 \(\mu\)g/ml for DAPA so final range for validation was selected at mixture containing 25-125 \(\mu\)g/ml for SITA and 2.5-12.5 \(\mu\)g/ml for DAPA. All prepared solutions were scanned between 200-400 nm and all spectra were derivatized to 1\textsuperscript{st} order. D\textsuperscript{1} absorbance were obtained at selected wavelength and mean D\textsuperscript{1} absorbance was plotted against concentration (To get mean D\textsuperscript{1} absorbance, procedure was repeated for five times)

2.5.2. Intermediate precision (Repeatability)
To adjudge the repeatability of analytical method, solution of linearity studies were analyzed for five time with same conditions. Mean D\textsuperscript{1} absorbance was recorded at all concentration for SITA and DAPA and were observed for relative standard deviation.

2.6. Method precision
Method precision was determined by performing intraday and interday precision. Mixture that represents overall range (2.5+25, 7.5+75 and 12.5+125 \(\mu\)g/mL) were analyzed on same day at different time interval for intraday precision. Mixture that represents overall range (2.5+25, 7.5+75 and 12.5+125 \(\mu\)g/mL) were analyzed on different days for interday precision.

2.7. Accuracy study
Accuracy of analytical method was adjudged by spiking of placebo with standard solution. Mixture containing 100 mg of directly compressible lactose, 2mg of talc and 2 mg of magnesium stearate was selected as placebo and was spiked at 50, 100 and 150% of target concentration (5+50 \(\mu\)g/mL) (Table 1). Placebo (un spiked) was analyzed at given wavelengths for any possible interference. Each spiked concentration was analyzed for three times and mean % recovery was observed at each spiked level.

2.8. Solvent stability
Solvent stability was determined by scanning the same solution prepared in selected solvent (methyl alcohol) at 3 different time interval that is at 0 hour, 6 hours and 24 hours. Mixture of 12.5+125 \(\mu\)g/ml solution of SITA and DAPA in methyl alcohol were scanned at selected time interval and characteristics of spectra were compared (\(\lambda_{max}\)).

2.9. Assay
As the proposed synthetic mixture is having dose of 10 mg of DAPA and 100 mg of SITA, was mixed with selected placebo, and diluted appropriately to give mixture containing 125 \(\mu\)g/ml of SITA and 12.5 \(\mu\)g/ml of DAPA. This mixture was scanned between 200-400 nm and was derivatized to 1\textsuperscript{st} order. D\textsuperscript{1} absorbance was measured at selected wavelengths and were transformed to concentration with help of linear regression equation. This mixture was analyzed for three times and mean % assay was drawn.

3. Result and Discussion

3.1. Selection of analytical wavelength
Three different ZCP at 232 nm, 263 nm and 291 nm were observed in overlain D\textsuperscript{1}spectra of SITA (Figure 1). Three different ZCP at 256 nm, 275 nm and 305 nm were observed in overlain D\textsuperscript{1}spectra of DAPA (Figure 2). For determination of analytical wavelength D\textsuperscript{1} spectra of SITA and DAPA were overlapped (Figure 3). But there is very less difference between absorbance values of DAPA at 291 nm and hence difficulty in quantifying the same. Discussed problem can be eliminated at 232 nm, where the D\textsuperscript{1} absorbance values of DAPA are linear with significant difference (Figure 4). In similar way at ZCP of DAPA, linearity was observed only at 275 nm for SITA (Figure 5). So 232 nm and 275 nm were selected as analytical wavelength for quantitative determination of DAPA and SITA respectively.

3.2. Analytical method validation
All validation parameters were studied as per ICH guidelines.\textsuperscript{25,26}

3.3. Linearity and range
When D\textsuperscript{0}spectra of SITA was taken between 25 - 150 \(\mu\)g/mL, non-linearity was observed over 150 \(\mu\)g/mL. So, linearity for SITA was observed between 25 - 150 \(\mu\)g/mL. For method development purpose range was selected between 25 - 125 \(\mu\)g/mL (based on beer — lambert’s law). In similar way D\textsuperscript{0}spectra of DAPA was taken between 2.5 - 20 \(\mu\)g/mL, but non-linearity was observed over 20 \(\mu\)g/mL. So, linearity for DAPA was observed between 2.5 - 12.5 \(\mu\)g/mL (based on beer — lambert’s law). So final range for validation was selected at mixture containing 25 - 125 \(\mu\)g/ml for SITA and 2.5-12.5 \(\mu\)g/ml for DAPA (Figure 6). When calibration curve was plotted for given concentration range (Figures 7 and 8),
value of linear regression coefficient was found to be 0.9989 for SITA and 0.9991 for DAPA. Regression equation was found to be $y = 0.0003X + 0.0018$ for SITA and $y = 0.0027X + 0.0009$ for DAPA. Linearity data for both drugs is shown in Tables 2 and 3.

3.4. Repeatability

When all mixtures were analyzed at all concentration, calculated relative standard deviation at each level was found to be less than 2 so that method was found to be repeatable over the range of 25 - 125 $\mu$g/ml for SITA and 2.5 - 12.5 $\mu$g/ml for DAPA. Repeatability data are shown in table 4 and 5 for SITA and DAPA respectively.

3.5. Method precision

For determining inter day and intraday precision, % RSD was monitored at selected concentration level which was found to be less than 2 so method was found to be precise for estimation of SITA and DAPA. Data for intermediate precision are given in Tables 6 and 7 for SITA and DAPA respectively.

3.5.1. Accuracy study

Spiked placebo with standard solution at 50, 100 and 150% level was analyzed for % recovery which was found within 98 to 102, so method was found to be accurate (Table 8).

3.5.2. Solvent stability

As the $\lambda_{max}$ was stable over period of 24 hrs, the solvent was found to be suitable and drug was found to be stable.

3.5.3. Assay

When prepared synthetic mixture was analyzed by developed and validated method, % assay was found to be 100.0 ± 0.6 for SITA and for 100.1 ± 0.7 DAPA (Table 9).

4. Summary and Conclusion

The 1st order derivative spectroscopic method was developed and validated as per ICH Q2 R1 guidelines and was successfully applied for determination of SITA and DAPA from its synthetic mixture. Present method was found to be economical in terms of cost and time. Commonly used excipient didn’t interfere in estimation of SITA and DAPA so method was found to be specific. Method was also found to be repeatable and precise.

5. Acknowledgment

Authors are extremely grateful to Cadila Healthcare Ltd. for providing gift sample of DAPA and SITA without them this work would not have taken place. We are also thankful to overall research team who have contributed in either of the way. The authors are also grateful to Smt. S.M. Shah Pharmacy College for providing excellent research facilities and promoting research activities.

6. Author contributions

1. Shivani Jani- Collection of all the data after the completion of the research work and the preparation of manuscript was done by Shivani Jani.
2. Rashmi Shukla- After designing the project, execution of project was carried out by Rashmi Shukla.
3. Pinak Patel- The design of the study from choosing the drug to choosing the method was done by Pinak Patel.
4. Binny Mehta- After completion of the study, analysis of the data obtained from UV was done by Binny Mehta.
5. Krunal Detholia- During the study, synthetic mixture preparation according to the dose of the drugs was done by Krunal Detholia.

7. Source of Funding

None.

8. Conflict of Interest

None.

References

1. Ravinandan AP, Basavanagowda GM, Jimmy OD. Review on Sitagliptin. Int J Pharm Res Scholars. 2014;3(2):577–81.
2. Theodosios D, Filippatos EN, Liberopoulos MSE. Dapagliflozin in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab. 2015;6(1):29–41. doi:10.1177/2042018814558243
3. Serge A, Jennifer EH, Parikh S. Dapagliflozin is effective as add on therapy to Sitagliptin with Metformin: A 24-week, Multicenter, Randomized, Double -blind, Placebo controlled study. Diab Care. 2014;37:740–50.
4. Jani BR, Shah KV, Kapupara PP. Development and validation of UV spectroscopic first derivative method for simultaneous estimation of Dapagliflozin and Metformin hydrochloride in synthetic mixture. J Bio equiv. 2015;4(3):1569–76.
5. Bodade BJ, Da K, Chaudhari SS. Quantitative Estimation of Dapagliflozin in blood plasma by using UV Spectroscopy. Pharma Analytica Acta. 2019;10(2):2153–2435.
6. Sanagapati M, Dhanalakshmi K, Kavitha B. Method Development and validation of Dapagliflozin API by UV spectroscopy. Int J Pharm Sci Drug Res. 2014;6(3):250–2.
7. Mante GV, Gupta RK, Henike AT. Estimation of Dapagliflozin from its Tablet Formulation by UV spectroscopy. Pharm Methods. 2017;8(2):102–7.
8. Sundar S, Vasanthi P, Algar R, Kao D, Dutt R. Development and validation of RP-HPLC method for simultaneous estimation of Dapagliflozin and Metformin in bulk and in synthetic mixture. World J Pharm Pharm Sci. 2017;6(7):2139–50.
9. Suma BV, Deveswar R, Shenoy A. A new High Performance Thin Layer Chromatographic Method Development and Validation of Dapagliflozin in bulk and tablet dosage from. Int J Pharm Sci. 2019;11(5):58-63.
10. Mante GV, Henke AT, Umekar MJ. RP-HPLC Method for Estimation of Dapagliflozin from its Tablet. Int J ChemTech Res. 2018;11(01):242–8.
11. Nalla S. A Stability Indicating Rp-Hplc Method For Simultaneous Estimation Of Velpatasvir And Sofosbuvir In Combined Tablet Dosage Forms. *World J Pharm Pharm Sci.* 2017;4:1596–1611.

12. Parmar SH, Luhar D. Dr Narkheda SB. Development and Validation of UV-spectroscopy first derivative and High Performance Thin Layer Chromatography analytical method for simultaneous estimation of Dasagliflozin propanediol monohydrate and Saxagliptin hydrochloride in synthetic mixture. *Eur J Biomed Pharm Sci.* 2018;5(5):668–81.

13. Zameeruddin M, Sandhya S, Vishwanath B, Hajera N, Sandip T. Development and validation of UV spectroscopic method for simultaneous estimation of Dasagliflozin and Saxagliptin in synthetic mixture. *Int J Chem Pharm Anal.* 2019;8(1):59–66.

14. Rathor S, Patil P, Chapada V. Development and Validation of HPTLC method for the estimation of Sitagliptin Phosphate and Simvastatin in bulk and marketed formulation. *Int J Drug Dev Res.* 2012;4(3):292–7.

15. Tarkase KN, Saroda MB, Sa G, Gawade A. Development and Validation of UV spectrophotometric method for estimation of Sitagliptin Phosphate. *Der Pharmacia Lettre.* 2010;3(3):315–8.

16. Arul CG, Thangavel P, Murugesan J, Srinivasan K, Thangavel S. Analytical method for determination of Sitagliptin An Updated Review. *Int J Pharm Sci Res Rev.* 2017;43(1):217–25.

17. Rechal RC, Rao GM. Development and Validation of spectroscopic method for simultaneous estimation of Gliclazide and Sitagliptin Phosphate monohydrate in bulk and pharmaceutical dosage form. *Int J Pharm Pharm Sci.* 2015;7(6):372–6.

18. Reddy B, Raman N, Kumar BS, Chintal R. Chiral separation of Sitagliptin phosphate enantiomer by HPLC using amylose based chiral stationary phase. *J Pharm Res.* 2013;7(6):546–50. doi:10.1016/j.jpr.2013.06.018.

19. Srishia RG, Vasanth PM, Ramesh T, Malothu R. RP-HPLC method development and validation for simultaneous estimation of Metformin and Sitagliptin in tablet dosage forms. *Int J Pharm Res Anal.* 2013;3(3):8–12.

20. Jalkote RN, Kalshetti D. UV Spectrophotometric method development and validation for determination of Metformin in API and in pharmaceutical dosage form. *World J Pharm Pharma Sci.* 2019;8(5):916–25.

21. Raja T, Rao L. Validation HPTLC method for simultaneous estimation of Metformin hydrochloride and Sitagliptin phosphate in bulk drug and formulation. *Rasayan J Chem.* 2012;5(3):407–13.

22. Karimulla SK, Vasanth PM, Ramesh M. Method development and validation of Sitagliptin and Metformin using reverse phase HPLC method in bulk and tablet dosage form. *Scholar Res Libr Der Pharm Lettre.* 2013;5(5):168–74.

23. Abirami G, Vetrichelvan T. Validated HPTLC method for simultaneous estimation of Sitagliptin phosphate and Simvastatin in tablet dosage form. *Scholar Res Libr Der Pharm Lettre.* 2016;8(4):6–12.

24. GUIDELINE: validation of analytical procedure: Text and Methodology Q2(R2); 2005. Available from: https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf.

25. 2015. Available from: https://www.fda.gov/files/drugs/published/Analytical-Procedures-and-Methods-Validation-for-Drugs-and-Biologics.pdf.

26. Sowjanya G, Ganapaty S, Almas S. Derivative UV Spectroscopic approaches in multicomponent analysis -A review. *Int J Pharm Pharm Sci.* 2019;11(2):1–11.

**Author biography**

Shivani Jani, Assistant Professor

Rashmi Shukla, Assistant Professor

Pinak Patel, Professor

Binny Mehta, Associate Professor

Krunal Detholia, Professor

**Cite this article:** Jani S, Shukla R, Patel P, Mehta B, Detholia K. Quantitative estimation of sitagliptin and dapagliflozin propanediol monohydrate in synthetic mixture using 1st order derivative spectroscopy simultaneous spectrophotometric analysis. *Int J Pharm Chem Anal* 2022;9(1):28-34.